Males with lupus nephritis had higher all-cause mortality and proportion of infection-related death compared to females.

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Drug interactions, patient characteristics, and steroid use are critical in LN management, influencing treatment choices and outcomes. Nephrologists focus on renal preservation, while ...

Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on the development of the drug in ...

“We are thrilled to achieve this milestone that will provide access to LUPKYNIS in Japan, where there is a high rate of lupus nephritis among Japanese lupus patients. Our successful strategic ...

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody ...

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis The REGENCY study met its primary endpoint, demonstrating ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.

Having lupus may increase your risk of food allergies. And certain foods may trigger lupus flares. Learn more.

Now, the company has hit the brakes on its phase 2b study of the drug in lupus nephritis following four patient fatalities. An independent data monitoring committee (IDMC) recommended suspending ...